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Abstract: Loss of Y-chromosome (LOY) is associated with increased cancer mortality in males.
The prevalence of LOY in male breast cancer (BC) is unknown. The aim of this study is to assess the
presence and prognostic effect of LOY during male BC progression. We included male BC patients
diagnosed between 1989 and 2009 (n = 796). A tissue microarray (TMA) was constructed to perform
immunohistochemistry and fluorescent in situ hybridization (FISH), using an X and Y probe. We
also performed this FISH on a selected number of patients using whole tissue slides to study LOY
during progression from ductal carcinoma in situ (DCIS) to invasive BC. In total, LOY was present in
12.7% (n = 92) of cases, whereby LOY was associated with ER and PR negative tumors (p = 0.017 and
p = 0.01). LOY was not associated with the outcome. Using whole slides including invasive BC and
adjacent DCIS (n = 22), we detected a concordant LOY status between both components in 17 patients.
In conclusion, LOY is an early event in male breast carcinogenesis, which generally starts at the DCIS
stage and is associated with ER and PR negative tumors.
Keywords: male breast cancer; loss of Y-chromosome; ductal carcinoma in situ; invasive breast
cancer; progression
1. Introduction
Male breast cancer (BC) is a relatively rare disease that accounts for less than 1% of all BCs [1,2]. It is
generally diagnosed at a later stage compared to female BC, which worsens the outcome [2,3]. Male BC
is generally estrogen-receptor (ER) positive, progesterone receptor (PgR) positive, androgen receptor
(AR) positive, and human epidermal growth factor receptor 2 (HER2) negative [1,3–5]. Historically,
male BC literature was restricted to small single-center studies, thus data regarding male BC biology
are relatively limited.
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Loss of Y-chromosome (LOY) has previously been described in several solid tumors, including
esophageal carcinoma, pancreatic cancer, urothelial bladder cancer, colorectal cancer, and prostate
cancer [6–11]. Early case reports described the presence of LOY in male BC tissue [10–12]. A larger,
more recent study reported LOY in 5 out of 31 patients with male BC. They suggested that LOY
could lead to the loss of a candidate tumor suppressor gene (TMSB4Y), resulting in increased cell
proliferation [13]. Additionally, they reported LOY in the corresponding ductal carcinoma in situ
(DCIS) component in one male BC case, suggesting that LOY could be an early event in male breast
carcinogenesis [13]. In the peripheral blood of males, LOY has been reported to be associated with
an increased risk of all-cause mortality and non-hematological cancer mortality [14]. Although this
study does not mention male BC, they conclude that LOY could become a predictive biomarker for
male carcinogenesis. Nonetheless, the presence and role of LOY during breast carcinogenesis remain
poorly understood.
The aim of this study was, therefore, to assess the presence and potential prognostic effect of LOY
in male BC using a large cohort of patients. Secondary, we studied the presence of LOY during the
progression from DCIS to invasive BC by performing fluorescent in situ hybridization (FISH) on paired
DCIS and invasive BC.
2. Results
2.1. General Patients and Tumor Characteristics
A total number of 796 patients were included. Table 1 includes general clinicopathological features
of this cohort. The median age at diagnosis was 67 years (range 25 to 98 years). Within this cohort,
46.0% of cases had a breast cancer precursor lesion adjacent to the invasive component. The majority of
these precursor lesions (98.4%) were classified as DCIS. Median follow up time was 89 months (range
0 to 323 months), in which 62.1% of the patients died. Recorded breast cancer specific survival was
available for only 96 patients, of which 49 patients died due to breast cancer progression.
2.2. LOY in Male BC and Outcome
The presence of LOY was detected in 12.7% (92 out of 722) of patients. These patients had a median
age of 64 years (range 34-98 years). There was a significant association between LOY and ER and PR
status (p = 0.017 and p = 0.01, respectively), whereby LOY was associated with ER and PR negative
tumors. There was no significant association between LOY and other tumor characteristics, although
there was a trend for an association with tumor grade (p = 0.056) (Table 2). In addition, there was
no association between LOY and overall survival, recurrence-free survival or breast cancer-specific
survival (Hazard Ratio: 1.23 (95% Confidence Interval (CI) 0.86–1.48), 1.12 (95%CI 0.86–01.46) and 0.47
(95%CI 0.17–1.33) respectively).
2.3. LOY during Progression from DCIS to Invasive BC
Out of the 92 patients with LOY based on TMA, 40 had an adjacent DCIS component in the whole
tissue slide. In 22 patients, LOY was analyzed on whole tissue slides, including DCIS and adjacent
invasive disease (remaining 18 cases were excluded due to limited tissue availability). Table 3A depicts
the results of the whole slide analysis of these 22 patients. All invasive BC cases (n = 22) with LOY
based on TMA also had LOY in the whole tissue slide. We did not find LOY in non-tumor breast tissue.
A concordant LOY status between IBC and adjacent DCIS was found in 17 out of 22 patients.
In these 17 patients, LOY was detected in both DCIS and invasive BC. A discordant LOY status was
detected in four patients. LOY was detected in these four invasive BCs, whereby the corresponding
DCIS component did not have LOY. The LOY status of the DCIS component of one case remained
undetermined. Figure 1 illustrates a case with a concordant (A and B) and a discordant (C and D)
status between the DCIS and the invasive component, respectively.
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Table 1. Clinic pathological baseline characteristics (n = 796).
Patients and Tumor Characteristics n Range/%
Age at diagnosis (in years)
Median-range 67 25–98
Tumor size (in mm) (missing; n = 413)
Median-range 20 1–110








TIL density (missing; n = 32)
Minimal-Mild 652 81.9
Moderate-Severe 112 14.1
ER status (missing; n = 54)
ER+ 694 93.5
ER− 48 6.5
PR status (missing; n = 42)
PR+ 548 72.7
PR− 206 27.3
AR status (missing; n = 45)
AR+ 533 71.0
AR− 218 29.0
HER2 status (missing; n = 24)
HER2+ 34 4.4
HER2− 738 95.6





Loss of Y (Undetermined; n = 74)
XY 630 87.3
X_ 92 12.7
Distant metastasis (missing; n = 494)
Yes 66 21.9
No 236 78.1
Survival (missing; n = 6)
Alive 296 37.5
Dead 494 62.5
Table 2. Association of loss of Y-chromosome (LOY) with male breast cancer (BC) clinicopathological
characteristics (n = 722).
Patient and Tumor Characteristics
XY Status p-Value
XY (Range/%) X_ (Range/%)
Age at diagnosis
0.311Median (years) 67.0 (25–95) 64.5 (34–98)
Tumor size (missing; n = 362)
0.093Median (mm) 20.0 (1–110) 21.0 (0–90)
Grade (missing; n = 26)
0.056
Low 161 (26.5) 13 (14.7)
Intermediate 306 (50.3) 53 (60.2)
High 141 (23.2) 22 (25.0)
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Table 2. Cont.
Patient and Tumor Characteristics
XY Status p-Value
XY (Range/%) X_ (Range/%)
Precursor lesion (missing; n = 24)
0.605
None 317 (52.0) 48 (54.5)
DCIS 287 (47.0) 40 (45.5)
Other 6 (1.0) 0 (0.0)
TIL density (missing; n = 28)
0.268Minimal-Mild 515 (85.0) 13 (54.2)
Moderate-Severe 91 (15.0) 11 (45.8)
ER status (missing; n = 41)
0.017ER+ 561 (94.4) 76 (87.4)
ER− 33 (5.6) 11 (12.6)
PR status (missing; n = 34)
0.01PR+ 448 (74.4) 53 (61.6)
PR− 154 (24.6) 33 (38.4)
AR status (missing; n = 32)
0.327AR+ 428 (67.9) 67 (72.8)
AR− 174 (27.6) 21 (22.8)
HER2 status (missing; n = 17)
0.542HER2+ 29 (4.7) 3 (3.3)
HER2− 585 (95.3) 88 (96.7)
IHC subtype (undetermined; n = 60)
0.242
ER+/-PR+/-HER2− 525 (90.7) 72 (86.7)
ER+PR+/-HER2+ 27 (4.6) 3 (3.6)
ER-PR-HER2+ 1 (0.2) 0 (0.0)
ER-PR-HER2− 26 (4.5) 8 (9.6)
Distant metastasis (missing; n = 451)
0.157Yes 54 (22.6) 3 (10.8)
No 189 (79.4) 25 (89.2)
Survival (missing; n = 5)
0.469Alive 240 (38.4) 30 (33.0)
Dead 386 (61.6) 61 (67.0)
Table 3. Whole slide LOY analysis of patients with invasive BC and adjacent ductal carcinoma in
situ (DCIS).
Patient DCIS Invasive BC
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Table 3. Cont.
































From patients without LOY in the invasive component based on TMA, we selected 20 cases
with adjacent DCIS in the whole tissue slide. None of these cases had LOY, neither in the invasive
component nor the DCIS component. Table 3B depicts the results of the whole slide analysis of the
20 patients without LOY.
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Figure 1. Representative images of a male breast cancer (BC) case with a concordant loss of
Y-chromosome (LOY) status between ductal carcinoma in situ (DCIS) (A) and invasive BC (B) and a
case with a discordant LOY status between DCIS (C) and invasive BC (D). Hematoxylin and eosin
staining, at a 15×magnification and insets of the corresponding XY fluorescent in situ hybridization
(FISH) images at a 63×magnification. The cell nuclei are depicted in blue (dapi), the X-chromosome
is depicted in green (Fluorescein-5-isothiocynate;FITC), and the Y-chromosome is depicted in red
(Texas red).
3. Discussion
The aim of our study was to assess the presence and prognostic effect of LOY during male BC
progression. Our study is the first to describe LOY in a large cohort of male BC patients. Previous
studies of LOY in male BC were restricted to blood samples, analyses of the invasive component only,
or included small numbers [10–13]. In the current study, LOY was detected in 12.7% of male BC cases,
whereby tumors with LOY were more likely to be ER and/or PR negative. This association suggests that
patients with LOY might have more aggressive tumors since ER-negative breast tumors are generally
associated with shorter overall survival [3,4,15]. Additionally, the presence of LOY in peripheral blood
was also recently associated with all-cause mortality and non-hematological cancer mortality [14,16].
However, in our series, there was no association between LOY and survival. A possible explanation
for the lack of association between LOY and outcome in our series are missing breast cancer-specific
outcome data for the majority of patients in this cohort. Furthermore, our data were restricted to
the presence of LOY in breast cancer tissues, whereas data regarding LOY in peripheral blood cells
was missing.
In our series of invasive male BC samples with LOY, about 43% were associated with an adjacent
DCIS component. We did not detect any LOY in non-tumor breast epithelia by XY analysis on whole
tissue slides. This is consistent with the results of Wong and colleagues, who also demonstrated that
LOY was restricted to malignant lesions [13]. We detected LOY in the DCIS component in the majority
(17 out of 22) of cases with LOY in the invasive component. This suggests that LOY in male BC tissue
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is a process that is mostly already present in the DCIS component, resulting in LOY in the invasive
component. Furthermore, this further supports that DCIS is a precursor lesion of invasive male BC,
which is in line with other studies that demonstrated similar molecular aberrations in DCIS and paired
invasive male BC [17,18]. This early role for LOY in male carcinogenesis was also previously suggested
by Wong and colleagues [13]. Using a functional assay, they showed that clonal LOY contributes
to breast carcinogenesis through the deletion of a Y-chromosome expressed tumor suppressor gene.
Together with our data, showing an early LOY, this suggests that LOY might contribute to male breast
carcinogenesis through dysregulation of the cell proliferation and differentiation mechanism.
The strength of our study is the size of our cohort. This study is by far the largest study reporting
on LOY in male BC, including the evolution of LOY during the progression of DCIS to invasive BC.
However, our study also had several limitations. First, outcome data are incomplete, as mentioned
above, which limits the analyses of the clinical impact of LOY. Second, we included BC samples
between 1989 and 2009, thus a substantial proportion of samples were relatively old. This hampered
the FISH analysis, resulting in the exclusion of 9.3% of cases due to undetermined XY status. Future
studies could also use in vitro models to confirm our findings. However, male BC is rare, making
the use of in vitro models, specifically for DCIS, challenging. Additionally, a comprehensive and
integrated genomic analysis could be performed to shed more light on the molecular mechanisms that
affect or might be affected by LOY in male BC.
4. Materials and Methods
4.1. Patients
This work was approved by the Medical Ethics Committee of the Erasmus MC (approval number
MEC 02.953). According to national guidelines, no informed consent was needed for this study.
This study included all Dutch male BC cases diagnosed with invasive BC between 1989 and 2009.
Central pathology review was performed based on whole tissue slides, including histologic subtype,
grade (according to Bloom and Richardson), the presence and type of BC precursor lesions, and density
of tumor-infiltrating lymphocytes (TILs), as described previously [5,19,20]. Other clinicopathological
data were collected by the Netherlands Comprehensive Cancer Organization (IKNL), including age at
diagnosis, tumor size, nodal status, and outcome.
Overall survival was defined as the time between initial diagnosis and death due to any cause.
Relapse free survival was defined as the time between initial diagnosis and ipsilateral recurrence,
metastasis, or death due to any cause. Breast cancer specific survival was defined as the time between
diagnosis and breast cancer specific death.
4.2. Immunohistochemistry on Tissue Micro-Array
A tissue microarray (TMA) of all invasive male BC cases was constructed and used to assess ER,
PR, AR, and HER2 status. An overview of these antibodies is depicted in Table 4. Briefly, 4 µm-thick
formalin-fixed paraffin-embedded (FFPE) TMA slides were dewaxed, and heat-induced antigen
retrieval was performed at antibody specific pH, varying from 6.0 to 9.0. The tissue samples were then
incubated with the primary antibody, followed by a hematoxylin counterstain, whereby DAB was
used as a chromogen. ER and PR status was classified as positive when the percentage of positive
tumor cells was at least 10%, according to Dutch guidelines [21]. The cut-off for AR positivity was
also set at 10% [3]. HER2 status was scored according to international guidelines [22]. For this study,
coded leftover patient material was used in accordance with the Code of Conduct of the Federation of
Medical Scientific Societies in The Netherlands [23].
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Table 4. Antibody characteristics and used protocol for immunohistochemistry.
Antibody Type Company Clone Lot Number Dilution AntigenRetrieval pH
Incubation
Time
ER Anti-mouse Dako 1D5 M7047 1:40 9 60 min
PR Anti-mouse Dako PgR 636 M3569 1:50 9 60 min
AR Anti-mouse ErasmusMC F39.4 Trapman 1:50 9 Overnight
HER2neu Anti-Rabbit Dako Herceptest K5204 ready to use ready to use 60 min
4.3. Fluorescent In Situ Hybridization on Invasive BC Using Tissue Micro-Array
We performed an XY specific FISH on a TMA of invasive male BC to determine LOY using the
Satellite Enumeration (SE) X (DXZ1)/ Y (DYZ3) FISH probe (catalog number: PI-KBI-20030 D1.1,
KreatechTM FISH probes, Leica Biosystems, Wetzlar, Germany). This dual-color probe contained a
green-labeled (DXZ1) probe for the X chromosome (at Xp11.1-q11.1 with PlatinumBright TM 495)
and a red-labeled (DYZ3) probe for the Y chromosome, (at Yp11.1-q11.1 with PlatinumBright TM
550). First, 4 µm-thick FFPE TMA slides were dewaxed and dehydrated, cooked for 13 min in citrate
buffer, and then treated with pepsin for 20 min. Hereafter, hybridization followed first at 75 ◦C for
10 min and then at 37 ◦C overnight in a Hybridizer (Dako Agilent, Stanta Clara, CA, United States).
Non-specific binding was removed by a stringent wash buffer at 73 ◦C. The slides were rinsed in a 2×
SCC, dehydrated, air-dried, and sealed with a cover glass. They were stored at 4 ◦C until further use.
For visualization and analysis, the stained slides were scanned by the Vectra 3 automated
quantitative pathology imaging system (Akoya biosciences, Malborough, MA, USA). Selected cores
were manually scored using Inform (Akoya biosciences, Malborough, MA, USA), whereby LOY was
defined as the absence of Y-chromosome in at least 75% of tumor cells. Figure 2 depicts representative
images scored as XY (A) or LOY (B).
Figure 2. Representative images of male BC cases with XY (A) and LOY (B), both at a 40×magnification.
The cell nuclei are depicted in blue (dapi), the X-chromosome is depicted in green (FITC), and the
Y-chromosome is depicted in red (Texas red).
Cancers 2020, 12, 631 9 of 11
4.4. Fluorescent In Situ Hybridization on Invasive BC and Adjacent DCIS Using Whole Tissue Slides
In total, 22 cases with LOY and 20 cases without LOY in the invasive component on TMA were
selected for further analyses to study the pattern of LOY during progression from DCIS to invasive BC.
For this purpose, we included patients with a DCIS component in the whole tissue section. The XY
FISH was performed on whole tissue sections to assess the presence of LOY in paired DCIS and
invasive BC cells. Figure 3 depicts the workflow of our study.
Figure 3. Study flowchart. TMA: tissue microarray.
4.5. Statistical Analysis
The Chi-square test was used to analyze associations between LOY and clinicopathological
features. The Mann-Whitney U test was used to compare continuous variables between patients
with LOY and those without LOY. A Cox proportional hazards regression was used to examine the
overall survival, recurrence-free survival, and breast cancer-specific survival. p-values < 0.05 were
considered significant.
5. Conclusions
In conclusion, we demonstrated that LOY is present in a substantial proportion (12.7%) of male
BC cases and that it was associated with ER and PR negative tumors. With regard to progression,
there was a concordant LOY status between the DCIS component and the paired invasive component
in the majority of cases. We, therefore, suggest that LOY is an early event, which starts in the DCIS
stage and mostly results in LOY at the invasive stage.
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